Eris Lifesciences announced impressive Q4 financial results, with revenue increasing 27.9% year-over-year to ₹705.00 crore. Net profit grew 31.1% to ₹93.80 crore, and EBITDA margin improved to 36.00%. For the full fiscal year, revenue grew 44% to ₹2,894.00 crore. The company provided guidance for the next fiscal year, projecting consolidated revenue between ₹3,325.00–3,500.00 crore and aiming to reduce net debt to ₹1,800.00 crore.
07Mar 25
Eris Lifesciences Reshuffles Holdings: Transfers Two Subsidiaries to Eris Therapeutics for Rs. 862 Crore
Eris Lifesciences has transferred its 100% holdings in Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL) to Eris Therapeutics Limited (ETL) for Rs. 862 crore. The transaction, agreed on March 6, 2025, is expected to complete by March 31, 2025. EOHPL contributed 3.6% to revenue and 2.0% to net worth, while AHL contributed 3.0% to revenue and 2.5% to net worth in the last financial year. The company also allotted 33,287 equity shares under its ESOP-2021 Scheme, increasing its paid-up share capital to Rs. 13,61,62,569.
Eris Lifesciences is selling its entire stake in two subsidiaries, Eris Oaknet Healthcare and Aprica Healthcare, to its wholly-owned subsidiary Eris Therapeutics for Rs 861.9 crore. The transaction is part of an internal reorganization to be completed by March 31, 2025. Despite a 49.61% revenue increase to Rs 727.45 crore in Q3 FY2025, the company's net profit fell by 18.61% to Rs 83.63 crore, largely due to a 215% surge in finance costs. Additionally, Eris allotted 33,287 equity shares under its ESOP-2021 scheme, increasing its paid-up share capital to Rs 13,61,62,569.